Page last updated: 2024-08-05 13:33:03
cyanopyridine
Any pyridine carrying at least one cyano substituent.
ChEBI ID: 23438
Members (3)
Member | Definition | Role |
---|---|---|
bay 60-6583 | A member of the class of cyanopyridines that is 6-amino-3,5-dicyano-4-(4-hydroxyphenyl)-2-sulfanylpyridine in which the hydroxy and sulfanyl hydrogens are replaced by cyclopropylmethyl and carboxamidomethyl groups respectively. | BAY 60-6583 |
chir 99021 | A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively. | CHIR 99021 |
ivosidenib | A tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. | ivosidenib |
Research
Studies (408)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 16 (3.92) | 29.6817 |
2010's | 253 (62.01) | 24.3611 |
2020's | 139 (34.07) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 23 (5.56%) | 5.53% |
Reviews | 26 (6.28%) | 6.00% |
Case Studies | 10 (2.42%) | 4.05% |
Observational | 1 (0.24%) | 0.25% |
Other | 354 (85.51%) | 84.16% |